CCL2



CCL2

Q1QQ1P2PP2D3DD3A4AA4I5II5N6NN6A7AA7P8PP8V9VV9T10TT10C11CC11C12CC12Y13YY13N14NN14F15FF15T16TT16N17NN17R18RR18K19KK19I20II20S21SS21V22VV22Q23QQ23R24RR24L25LL25A26AA26S27SS27Y28YY28R29RR29R30RR30I31II31T32TT32S33SS33S34SS34K35KK35C36CC36P37PP37K38KK38E39EE39A40AA40V41VV41I42II42F43FF43K44KK44T45TT45I46II46V47VV47... and 29 more residue(s)...... and 29 more residue(s)

SMILES None
InChIKey None
Sequence QPDAINAPVTCCYNFTNRKISVQRLASYRRITSSKCPKEAVIFKTIVAKEICADPKQKWVQDSMDHLDKQTQTPKT

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections

Ligand site mutations CCR2


Bioactivities

CCL2

Q1QQ1P2PP2D3DD3A4AA4I5II5N6NN6A7AA7P8PP8V9VV9T10TT10C11CC11C12CC12Y13YY13N14NN14F15FF15T16TT16N17NN17R18RR18K19KK19I20II20S21SS21V22VV22Q23QQ23R24RR24L25LL25A26AA26S27SS27Y28YY28R29RR29R30RR30I31II31T32TT32S33SS33S34SS34K35KK35C36CC36P37PP37K38KK38E39EE39A40AA40V41VV41I42II42F43FF43K44KK44T45TT45I46II46V47VV47... and 29 more residue(s)...... and 29 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections

Ligand site mutations CCR2


Compound is not listed as a drug.